prescription drugs

The Speaker's proposal generated ample discussion around its potential impact.

One of the most notable data points was the nearly flat rate for average claim cost, increasing 0.8%, compared to...

Between 2011 and 2015, rebates for brand-name prescription drugs still increased $2 billion.

The big contributions that lawmakers are getting signal that the pharmaceutical industry is building loyalty ahead of the 2020 elections.

A survey found that specialty drugs have an outsized impact on employer prescription drug spending.

A first-of-its-kind intensive training program gives non-specialist pharmacists confidence to deal with complex and critical medication issues for ICU patients.

Critics say authorized generics hurt long-term competition and often perversely increase costs, even in the short term.

The bipartisan drug pricing bill passed the committee but faces industry opposition and uncertainty in the full Senate.

The ruling is likely to be challenged at the United States Court of Appeals for the District of Columbia Circuit.

After two flat years, the medical cost trend is expected to rise in 2020, according to PricewaterhouseCoopers.

Empire State lawmakers are considering legislation that would implement a fee-for-service program and effectively cut out PBMs.

Investment grade pharmaceutical companies continue to display a high capacity for M&A activity, according to a new Moody's report.